Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets

v3.23.1
Consolidated Balance Sheets - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Current Assets    
Cash and cash equivalents $ 221,065 $ 235,311
Accounts receivable 45,000
Marketable securities 154,123 148,808
Total Current Assets 375,188 429,119
Total Assets 375,188 429,119
Current Liabilities    
Accounts payable and accrued expenses 1,250,531 1,220,017
Accounts payable - related party 911,659 911,659
Short -term advances - related party 1,673,558 1,673,558
Convertible note payable 25,000 25,000
Convertible notes payable - related party, net of debt discount of $0 and $0, as of March 31, 2023 and December 31, 2022 173,192 173,192
Notes payable - related party - net of debt discount of $0 and $0 as of March 31, 2023 and December 31, 2022 106,850 106,850
Total Current Liabilities 4,140,790 4,110,276
Long Term Liabilities    
Convertible note payable, net of debt discount of $17,010 and $19,845 as of March 31, 2023 and December 31, 2022 482,990 480,155
Total Long-Term Liabilities 482,990 480,155
Total Liabilities 4,623,780 4,590,431
Commitments and Contingencies (Note 8)
Stockholders’ Deficit    
Preferred stock, $0.0001 par value, 50,000,000 shares authorized, none issued and outstanding as of March 31, 2023 and December 31, 2022
Common stock, $0.0001 par value: authorized 500,000,000, 21,674,000 and 21,674,000 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively 2,167 2,167
Additional paid-in capital 810,048 810,048
Accumulated deficit (5,060,807) (4,973,527)
Total Stockholders’ Deficit (4,248,592) (4,161,312)
Total Liabilities and Stockholders’ Deficit $ 375,188 $ 429,119